Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

MeSH terms

• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use
• Dasatinib* / administration & dosage
• Dasatinib* / adverse effects
• Dasatinib* / therapeutic use
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
• Protein Kinase Inhibitors* / administration & dosage
• Protein Kinase Inhibitors* / adverse effects
• Protein Kinase Inhibitors* / therapeutic use
• Treatment Outcome